Viewbix: Quantum X Labs Announces Provisional Patent Filing for Quantum-Enhanced Clinical Trials Technology

Rhea-AI Summary

Viewbix (NASDAQ: VBIX) announced that Quantum X Labs filed a provisional patent on Dec 22, 2025 titled "Generating Quantum Markov Chain Monte Carlo Sampling Points for Continuous Distribution Functions". The technology applies quantum-enhanced MCMC to sample complex continuous probability distributions and is being developed with portfolio company Cliniquantum to map biological data, identify latent patient clusters, and model probabilistic treatment responses with higher resolution.

Viewbix signed a definitive agreement on Dec 15, 2025 to acquire 85%–100% of Quantum X Labs; the acquisition is expected to close within 90 days of execution, subject to due diligence, regulatory approvals, and stockholder approval under Nasdaq rules.

Positive

• Provisional patent filed on Dec 22, 2025
• Definitive agreement for 85%–100% acquisition executed Dec 15, 2025
• Patent portfolio includes prior quantum error correction IP
• Acquisition closing expected within 90 days of execution

Negative

• Closing subject to due diligence, regulatory approvals, and stockholder vote
• Acquisition outcome depends on Nasdaq rules and customary closing conditions

Key Figures

Stake to be acquired up to 100% Definitive agreement to acquire Quantum X Labs

Minimum stake not less than 85% Definitive agreement to acquire Quantum X Labs

Expected closing window within 90 days From definitive agreement dated <b>December 15, 2025</b>

Market Reality Check

$1.06 Last Close

Volume Volume 23,621 is about 0.18x the 20-day average of 129,708, indicating subdued trading ahead of this IP announcement. low

Technical Shares at $1.06 are trading below the 200-day MA of $3.93 and sit far under the $12.00 52-week high.

Peers on Argus

Peers show mixed moves: SCOR +1.24%, ZDGE +6.84%, while SJ -2.42% and FENG -0.75%. With VBIX down 1.85%, the action appears more stock-specific than sector-driven.

Market Pulse Summary

This announcement outlined a provisional patent for quantum-enhanced MCMC methods and an agreement to acquire between 85% and 100% of Quantum X Labs within 90 days of the December 15, 2025 agreement date. Investors may focus on how this technology integrates with clinical trial applications, whether closing conditions are satisfied, and how a company trading below its $3.93 200-day MA funds and executes this strategy.

Key Terms

provisional patent regulatory

"Quantum X Labs has filed a provisional patent application titled"

A provisional patent is a temporary filing that locks in an early priority date for an invention and lets a company label the technology as "patent pending" while it develops the idea and prepares a full patent application. It matters to investors because it signals an intent to protect intellectual property with relatively low initial cost and a limited window to convert to a full patent; it can reduce the risk of being preempted by others but does not guarantee long-term legal protection.

quantum computing technical

"This innovative technology leverages quantum computing to enhance Markov Chain"

Quantum computing is a type of advanced technology that uses the principles of quantum physics to perform calculations much faster than traditional computers. It can process vast amounts of information simultaneously, potentially solving complex problems that are currently impossible or take too long with regular computers. For investors, this technology could lead to breakthroughs in areas like cryptography, data analysis, and optimization, impacting financial markets and security systems.

markov chain monte carlo technical

"enhance Markov Chain Monte Carlo (MCMC) methods, enabling more efficient sampling"

A Markov Chain Monte Carlo (MCMC) method is a way to simulate many possible outcomes from a complex probability model by taking a sequence of random steps that gradually explores the most likely scenarios, like a hiker using many short, guided walks to map an unexplored landscape. For investors it matters because MCMC helps quantify uncertainty and estimate probabilities for pricing, risk, and forecasts when formulas are too complex to solve directly, improving decisions under uncertainty.

clinical trials medical

"pioneering the application of this quantum-enhanced approach to potentially revolutionize clinical trials."

Clinical trials are carefully controlled studies that test whether a new drug, device or treatment is safe and effective in people, moving through successive stages that increase the number of participants and the rigor of testing. Investors care because trial outcomes determine whether a product can be approved and sold, shaping a company’s future revenue, valuation and risk profile—think of it as proof-of-concept testing that decides if a prototype becomes a market-ready product.

quantum error correction technical

"including prior IP in quantum error correction."

Quantum error correction is a set of methods for detecting and fixing mistakes in quantum computers by encoding fragile quantum information across multiple physical parts, much like using multiple copies or checksums to protect a sensitive digital file. For investors, it matters because reliable error correction is a key technical milestone that determines whether quantum machines can scale from experimental devices to practical tools that could disrupt computing, encryption, drug discovery and other industries.

regulatory approvals regulatory

"subject to final due diligence, regulatory approvals, the approval of the Company’s"

Regulatory approvals are official permissions from government agencies that a company needs before launching a new product, service, or business activity. They matter because without this approval, the company might not be allowed to operate legally or sell its products, similar to how a driver needs a license to legally drive a car.

AI-generated analysis. Not financial advice.

This advancement has the potential to transform conventional "flat" clinical trial data into detailed quantum-resolved biological maps

Tel Aviv, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Viewbix Inc. (Nasdaq: VBIX) (“Viewbix” or the “Company”), an advanced technologies company, announced today a significant intellectual property milestone achieved by Quantum X Labs.

Quantum X Labs has filed a provisional patent application titled "Generating Quantum Markov Chain Monte Carlo Sampling Points for Continuous Distribution Functions".

This innovative technology leverages quantum computing to enhance Markov Chain Monte Carlo (MCMC) methods, enabling more efficient sampling from complex continuous probability distributions.

In collaboration with its portfolio company Cliniquantum, Quantum X Labs is pioneering the application of this quantum-enhanced approach to potentially revolutionize clinical trials. The methodology aims to uncover hidden biological structures and non-linear dependencies across molecular and patient data layers, allowing for the identification of latent patient clusters, precise molecular response signatures, and probabilistic treatment-response modelling- with higher resolution and potentially requiring fewer samples than traditional classical methods.

This advancement has the potential to transform conventional "flat" clinical trial data into detailed quantum-resolved biological maps, converting historically underpowered datasets into robust mechanistic evidence. As quantum computers mature and process vast configurations in parallel, this technology positions Viewbix, through its proposed acquisition of Quantum X Labs, to capture significant value in the pharmaceutical and drug discovery markets by accelerating personalized medicine, reducing trial costs and timelines, and improving success rates.

Viewbix recently signed a definitive agreement to acquire up to 100% (and not less than 85%) of Quantum X Labs, encompassing its expanding patent portfolio, including prior IP in quantum error correction. The acquisition is expected to close within 90 days of the date of execution of the definitive agreement, which was December 15, 2025, subject to final due diligence, regulatory approvals, the approval of the Company’s stockholders in accordance with applicable rules or regulations of the Nasdaq Stock Market LLC and customary closing conditions.

About Viewbix Inc.

Viewbix Inc. (Nasdaq: VBIX) is an advanced technologies company that, through certain of its subsidiaries Gix Media Ltd. and Metagramm Software Ltd., operates in the field of digital advertising. Gix Media develops a variety of technological software solutions, which perform automation, optimization and monetization of internet campaigns, for the purposes of acquiring and routing internet user traffic to its customers. Metagramm is a developer of grammatical error correction software. The company offers tools for writing and reviewing, grammar, spelling, punctuation and style features, as well as translation and multilingual dictionaries, using artificial intelligence and machine learning technology.

For more information about Viewbix, visit https://view-bix.com/
More information about Quantum X Labs visit: https://quantumxlabs.xyz/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995 and other Federal securities laws. Words such as “expects,” “anticipates,” “intends,” “plans,” “believes,” “seeks,” “estimates” and similar expressions or variations of such words are intended to identify forward-looking statements. For example, the Company is using forward-looking statements when it discusses the timing and completion of the acquisition, the receipt of regulatory approvals, the receipt of approval by the Company’s stockholders and the satisfaction of closing conditions related to the acquisition. Because such statements deal with future events and are based on Viewbix’s current expectations, they are subject to various risks and uncertainties, and actual results, performance or achievements could differ materially from those described in or implied by the statements in this press release.

The forward-looking statements contained or implied in this press release are subject to other risks and uncertainties, including those discussed in any filings with the SEC. Except as otherwise required by law, Viewbix undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. References and links to websites have been provided as a convenience, and the information contained on such websites is not incorporated by reference into this press release. Viewbix is not responsible for the contents of third-party websites.

Investor Relations Contacts:
Michal Efraty
Investor Relations
michal@efraty.com

FAQ

What did Viewbix (VBIX) announce on Dec 22, 2025 about Quantum X Labs?

Viewbix announced a provisional patent filing by Quantum X Labs for a quantum-enhanced MCMC method and disclosed a definitive agreement to acquire 85%–100% of Quantum X Labs.

What is the provisional patent title filed Dec 22, 2025 for Quantum X Labs (VBIX)?

The provisional patent is titled "Generating Quantum Markov Chain Monte Carlo Sampling Points for Continuous Distribution Functions."

How much of Quantum X Labs is Viewbix (VBIX) agreeing to acquire and when was the agreement signed?

Viewbix signed a definitive agreement on Dec 15, 2025 to acquire not less than 85% and up to 100% of Quantum X Labs.

When is the Viewbix (VBIX) acquisition of Quantum X Labs expected to close?

The acquisition is expected to close within 90 days of the Dec 15, 2025 execution date, subject to conditions.

How will the Quantum X Labs technology be applied in clinical trials according to Viewbix (VBIX)?

The technology aims to produce quantum-resolved biological maps, identify latent patient clusters, and enable probabilistic treatment-response modelling with fewer samples.

What approvals does Viewbix (VBIX) need before completing the Quantum X Labs acquisition?

Completion requires final due diligence, regulatory approvals, and approval by the company's stockholders in accordance with Nasdaq rules.